Table 1:

Summary of current efficacy data of commercial CAR-T products^*

CAR-T product	Disease(s) treated	Antigen target	Survival data
Tisagenlecleucel†4,5	B-ALL and high-grade B-cell lymphoma	CD19	76% OS at 1 year in B-ALL Median OS of 8.3 mo in high-grade B-cell lymphoma
Axicabtagene ciloleucel†6	High-grade B-cell lymphoma	CD19	58% OS at 18 mo
Brexucabtagene autoleucel†7	Mantle cell lymphoma	CD19	83% OS at 1 yr
Idecabtagene vicleucel†8	Multiple myeloma	BCMA	Median PFS of 11.8 mo
Lisocabtagene maraleucel‡9	High-grade B-cell lymphoma	CD19	Median OS of 18.8 mo

Note: B-ALL = B cell acute lymphoblastic leukemia, BCMA = B-cell maturation antigen, CAR-T = chimeric antigen receptor T-cell therapy, FDA = US Food and Drug Administration, OS = overall survival, PFS = progression-free survival.

^*All diseases treated have relapsed or are refractory. All studies are single-arm, nonrandomized clinical trials.

^†Health Canada and FDA approval.

^‡FDA approval only.